ALT ▼ -1.9% - Altimmune, Inc.
$ALT - Altimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026
05-NOV-2026 10:00 AM ET
Share this post
More filings for $ALT
ALT ▲ +0.5% - Altimmune, Inc.Nov 5, 2026ALT ▲ +1.4% - Altimmune, Inc.Oct 19, 2026ALT ▼ -0.3% - Altimmune, Inc.Sep 23, 2026
View full $ALT filing history →💬 Comments
Loading comments…
Leave a comment